IMPACT Study: The Immune Profiling with Antibody-based COVID-19 Testing - COVID-19 antibodies test
Updated: May 23, 2022
IMPACT STUDY
The Immune Profiling with Antibody-based COVID-19 Testing (IMPACT) study
The Immune Profiling with Antibody-based COVID-19 Testing (IMPACT) study
The Immune Profiling with Antibody-based COVID-19 Testing (IMPACT) study will investigate the short and long-term impact of COVID-19 of a population who is at risk of developing myeloma or who has a precursor condition to myeloma.
This population may be more susceptible to complications after exposure to the virus that causes COVID-19 or during recovery from the disease. Precursor conditions for multiple myeloma include monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma.
Learn more to Enroll here:
Dana-Farber Cancer Institute/Harvard Cancer Center Boston
IMPACT is investigating how the virus affects the immune system and how people with risks for blood cancer may respond to COVID-19 and its emerging vaccines.
The IMPACT study is an affiliate study of the PROMISE and PCROWD Studies. We will analyze blood samples for up to one year to learn how COVID-19 exposure affects the immune system.
All participants enrolled in IMPACT will receive a free antibody test to determine if they have been exposed to the virus that causes COVID-19.
Dana-Farber Cancer Institute and Quest Diagnostics collaborate to identify the prevalence of COVID-19 in individuals with precursor to multiple myeloma
The IMPACT study is an affiliate study of the PROMISE and PCROWD Studies.
NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population
The PCROWD Study invites people with precursor conditions to Share samples a few times each year
- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston